Addex Therapeutics
Pipeline Clinical and Pre-Clinical Pipeline Research And Development Publications Dipraglurant (mGlu5 NAM) - Post-Stroke / TBI Recovery ADX71149 (mGlu2 PAM) GABAB PAM - Substance Use Disorder GABAB PAM - Chronic Cough Technology Allosteric Modulation Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.
Basic Information
- Category: public company
- Website: http://www.addexpharma.com/
Documented Facts
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: V8 (No linked source recorded for this statement.)
- Stock ticker: ADXN (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- Addex Therapeutics — Official Site (official)
- Addex Therapeutics on linkedin (social)
- Addex Therapeutics Ltd. — SEC EDGAR (reference)
Citation Guidance
Explore public company profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Addex Therapeutics.
- Canonical profile: https://brandsource.ai/brands/addex-therapeutics
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/addex-therapeutics/json-ld
- Citation profile API: https://brandsource.ai/api/brands/addex-therapeutics/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (91/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Pipeline Clinical and Pre-Clinical Pipeline Research And Development Publications Dipraglurant (mGlu5 NAM) - Post-Stroke / TBI Recovery ADX71149 (mGlu2 PAM) GABAB PAM - Substance Use Disorder GABAB PAM - Chronic Cough Technology Allosteric Modulation Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.